-
Markets
-
Equities
Sustainable finance2025 Euronext ESG Trends ReportRead moreA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETFs
The European market place for ETFsEuronext ETF EuropeRead moreInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Funds
-
Fixed Income
European Defence BondsGroupe BPCE lists the first bondRead moreFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Structured Products
-
Derivatives
Where European Government Bonds Meet the FutureFixed Income derivativesRead moreTrade mini bond futures on main European government bonds
-
Commodities
- Overview
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Delivery & settlement
- Specifications & arrangements
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesRead moreEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Resources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameRead moreJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
EXACT Therapeutics AS: New option program and receipt of share options by primary insiders
24 Nov 2025 08:25 CET
Issuer
EXACT Therapeutics AS
24 November 2025: EXACT Therapeutics AS ("EXACT Tx" or the "Company") announces
that the Company as of today has introduced a new long-term incentive program in
the form of award of share options, each giving the right to purchase one share
in the Company at a strike price to be determined by the board of directors of
the Company, and with settlement in either shares in the Company or cash (the
"New Incentive Program"). The options will vest in tranches conditional upon the
participants continuous positions with the group, and are exercisable in
designated exercise windows, with the intention of following, inter alia, the
end of the quarter after the vesting periods. The Company wil issue a total of 1
069 643 options under the New Incentive Program.
The New Incentive Program replaces the current incentive program of the Company
(the "Current Incentive Program"). Thus, options held by certain primary
insiders of the Company under the Current Incentive Program will lapse
accordingly, while new options will be awarded to the respective participants,
including primary insiders, as further set out in the attached notifications of
trade.
This information is subject to the disclosure requirements in article 19 of the
EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading
Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com
More information:
Access the news on Oslo Bors NewsWeb site
Source
EXACT Therapeutics AS
Provider
Oslo Børs Newspoint
Company Name
EXACT THERAPEUTICS
ISIN
NO0010852213
Symbol
EXTX
Market
Euronext Growth